Quality of Life Group
Health-related quality of life in survivors of locally advanced breast cancer.
An international randomized controlled phase III trial.
EORTC study comparing two treatment regimens (dose-intensive chemotherapy versus standard chemotherapy of a combination treatment of yclophosphamide, epirubicin and fluorouraci, prior to operation), in patients with locally advanced breast cancer. Results showed that patients assigned to dose-intensive treatment had significantly lower health-related quality of life (HRQOL) scores during the first three months, but scores returned to near baseline with no difference between groups after 12 months. This was the first randomized trial to show that dose-intensive treatment may lead to temporary reduction of HRQOL scores.